NCT06233799View on ClinicalTrials.gov

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

April 30, 2027

Conditions
Methamphetamine-dependenceMethamphetamine Abuse
Interventions
DRUG

extended-release naltrexone (XR-NTX)

Once per three weeks injections of extended-release naltrexone

DRUG

extended release bupropion (BUP-XL) tablets (BUP-XL)

Daily oral extended release bupropion tablets

DRUG

iPLB

Once per three weeks injections of placebo

DRUG

oPLB

Daily oral placebo tablets

Trial Locations (11)

22903

RECRUITING

University of Virginia, Charlottesville

29671

RECRUITING

MUSC/BHS, Pickens

38119

RECRUITING

University of Tennessee, Memphis

46202

RECRUITING

Indiana University, Indianapolis

55415

RECRUITING

University of Minnesota, Minneapolis

66160

ACTIVE_NOT_RECRUITING

University of Kansas Medical Center, Kansas City

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

75247

RECRUITING

University of Texas Southwestern Medical Center, Dallas

90038

RECRUITING

University of California Los Angeles, Los Angeles

92037

RECRUITING

University of California at San Diego, San Diego

97214

RECRUITING

CODA, Portland

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH